Mirum Pharmaceuticals Announces Inducement Grants for New Employees Under 2020 Plan

Reuters
11 Jul
Mirum Pharmaceuticals Announces Inducement Grants for New Employees Under 2020 Plan

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) has announced the issuance of inducement awards to two new employees as part of their 2020 Inducement Plan. On July 10, 2025, the Compensation Committee of Mirum's Board of Directors granted non-qualified stock options to purchase 14,460 shares of common stock and 7,220 restricted stock units (RSUs). The stock options come with an exercise price of $53.01 per share and will vest over four years, with an initial 25% vesting after one year and the remainder vesting monthly over the subsequent 36 months. The RSUs will vest over three years, with 33% vesting on each anniversary of the vesting commencement date. These awards align with Nasdaq Listing Rule 5635(c)(4) and are contingent upon the employees' continued service with the company.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mirum Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250710074037) on July 10, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10